TOMSICEK MICHAEL JOHN 4

What Happened
Michael Tomsicek, a director of Milestone Pharmaceuticals, received a derivative award on 2026-06-10 covering 77,000 shares. The Form 4 reports the award at $0.00 (aggregate $0) — this is a grant/award (derivative), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-10; filing date: 2026-06-12 (filed promptly after the reported transaction).
• Transaction type/code: Grant/Award (A) of a derivative covering 77,000 shares; reported price $0.00 (aggregate $0).
• Shares owned after transaction: Not specified in the provided filing summary.
• Footnote: The option vests in twelve equal monthly installments beginning July 10, 2026; it will fully vest on the date of the next annual meeting if the reporting person remains in service.
• No 10b5-1, tax-withholding, or sale noted in this filing.

Context
This was an equity award to a director (common as part of board compensation), not a cash purchase or sale of stock. Because it’s a derivative grant with a time-based vesting schedule, the shares are not immediately owned outright and will only become exercisable/vest over the stated schedule (or at next annual meeting per the footnote) subject to continued service.